AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

CVE:NTBNeptune Technologies & Bioressources Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume31,049 shs
Average Volume315,395 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-450-6872262

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NTB News and Ratings via Email

Sign-up to receive the latest news and ratings for NTB and its competitors with MarketBeat's FREE daily newsletter.

Neptune Technologies & Bioressources (CVE:NTB) Frequently Asked Questions

How were Neptune Technologies & Bioressources' earnings last quarter?

Neptune Technologies & Bioressources Inc (CVE:NTB) issued its quarterly earnings data on Tuesday, July, 15th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million. View Neptune Technologies & Bioressources' earnings history.

Has Neptune Technologies & Bioressources been receiving favorable news coverage?

Headlines about NTB stock have trended extremely positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neptune Technologies & Bioressources earned a news impact score of 4.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View the latest news aboutNeptune Technologies & Bioressources.

What other stocks do shareholders of Neptune Technologies & Bioressources own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neptune Technologies & Bioressources investors own include ArQule (ARQL), Home Capital Group (HCG), Omnicell (OMCL), Storm Resources (SRX), ZIOPHARM Oncology (ZIOP), Acer Therapeutics (ACER), ACADIA Pharmaceuticals (ACAD), Air Canada (AC), Barrick Gold (ABX) and Arbutus Biopharma (ABUS).

Who are Neptune Technologies & Bioressources' key executives?

Neptune Technologies & Bioressources' management team includes the following people:
  • John Moretz, Chairman of the Board
  • James Stuart Hamilton, President, Chief Executive Officer, Director
  • Mario Paradis, Chief Financial Officer
  • Michel Timperio, Senior Vice President of Sales - Global Sales
  • Pierre Lemieux Ph.D., Chief Operating Officer of Acasti
  • Jean-Daniel Belanger, Corporate Secretary and Director - Corporate Affairs
  • Harlan W. Waksal M.D., Director (Age 61)
  • Valier Boivin, Independent Director
  • Ronald Denis, Independent Director
  • Adrian Taylor Montgomery, Independent Director

What is Neptune Technologies & Bioressources' stock symbol?

Neptune Technologies & Bioressources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."

How do I buy shares of Neptune Technologies & Bioressources?

Shares of NTB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Neptune Technologies & Bioressources' official website?

The official website for Neptune Technologies & Bioressources is neptunekrilloil.com.

How can I contact Neptune Technologies & Bioressources?

Neptune Technologies & Bioressources' mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The biotechnology company can be reached via phone at +1-450-6872262.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.